Discovery of potent measles virus fusion inhibitor peptides via structure-guided derivatization

Abstract

Fusion inhibitor peptide (FIP), a short peptide known as a measles virus (MeV) infection inhibitor, inhibits membrane fusion between the viral envelope of MeV and the host cell membrane. Therefore, FIP is potentially useful as a drug candidate for treating MeV infection, but improvement of inhibitory activity is desirable. In this study, we conducted a structure–activity relationship study of FIP and, based on the result and the previously reported crystal structure of the complex, we designed FIP derivatives. From a series of derivatives, we discovered an FIP derivative with a strong inhibitory activity (IC50 = 210 nM) derived from the enhanced binding affinity (KD = 6.6 nM) to the MeV fusion protein.

Supplementary files

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Research Article
Submitted
18 Dec 2024
Accepted
21 Jan 2025
First published
24 Jan 2025
This article is Open Access
Creative Commons BY license

RSC Med. Chem., 2025, Accepted Manuscript

Discovery of potent measles virus fusion inhibitor peptides via structure-guided derivatization

Z. Gao, J. Sasaki, T. Suzuki, T. Suzuki, Y. Miwa, S. Sando, T. Hashiguchi and J. Morimoto, RSC Med. Chem., 2025, Accepted Manuscript , DOI: 10.1039/D4MD01006J

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements